Launois B, Meunier B, Foglia M, Khelif D, Spiliopoulos Y, Stasik C, Lakehal M, Guezennec L, Camus C, Messner M
Centre de Chirurgie digestive et de l'Unité de Transplantation, C.H.U. de Rennes.
Chirurgie. 1996;121(3):207-14.
From 21st of april 1978 to 1st september 1994, 200 liver transplantations in 172 patients were performed in the Medical Center of University of Rennes. Three patients had a liver and kidney transplant. 26 patients received a second transplant (13%) and 2 patients a third transplant (1%). There were 110 males and 62 females with a mean age of 43.7 years (range 17 months-66 years). The indications of transplantations were the following: 22 fulminant hepatitis (12%), 104 cirrhosis (60.5%), including 41 alcoholic cirrhosis (24%), 21 post-hepatitis B cirrhosis (12.2%), 24 post-hepatitis C cirrhosis (14%), 6 autoimmune cirrhosis, 7 primary biliary cirrhosis (4%), 21 non A non B cirrhosis (12.9%), 3 undetermined cirrhosis. Thirty one patients had a liver transplantation for cancer. The other indications were 5 sclerosing cholangitis and 2 atresia of the biliary tract. 45% of the patients had an uneventful postoperative course. In hospital mortality rate is related to the indication and Child Pugh classification in cirrhotic patients. The vascular surgical complications were 8.5%, biliary complications 6.1%, intra-abdominal infection 9.2%, intra-abdominal bleeding 5.5%. The rate of reoperation was 18.5%. 23 re-transplantations were performed in emergency and 6 electively (one from outside). The overall survival of patients from 1978 to 1994, including the patients before cyclosporine era, the use of extracorporeal circulation, the preservation with Wisconsin solutions and with main indications for cancer was 69% at 1 year and 59% at 5 years. After 1988, the overall patient survival was 75% at 1 year and 70% at 5 years. The graft and patient survival is mainly related to the indications. In fulminant and subfulminant hepatitis, the quality of the graft was preferred as often as possible. The actuarial graft survival at 1 year, 3 years and 5 years was respectively 75%, 70.45% and 70.45%. The actuarial patient survival was 77.3%, 72.5% and 72.5%. In liver transplantation for cancer, the actuarial patient survival at 1 year, 3 years and 5 years is respectively 55%, 32% and 23.5%. 5 patients are alive and well at 5 years, including a patient who underwent a Cluster operation for Klatskin tumor. In post-hepatitis cirrhosis, the patient actuarial survival at 1 year, 3 years and 5 years was 79%, 76.5% and 76.5% and in alcoholic cirrhosis 75%, 72% and 72%. The actuarial survival is closely related to Child Pugh Classification (at one year Child A 87%, Child B 72.4%, Child C 58%).
in this series of the first 200 liver transplants at the University of Rennes Medical Center, graft and patient survival depends on the evolution of the surgical technic but it is also closely related to the indication. In fulminant hepatitis, the quality of the graft (without incompatible graft, if possible) should permit to avoid retransplantation and to obtain results closely to the elective transplantation. Liver transplantation for cancer should be restricted. In cirrhosis, results are depending upon Child Pugh classification. The conclusions of Paris consensus conference should be followed. The limited number of donor livers call for the "priorization" (T.E. Starzl) favoring those patients who will benefit most, i.e., patients with the most serious conditions and the poorest short term vital prognosis.
1978年4月21日至1994年9月1日,雷恩大学医学中心对172例患者实施了200例肝移植手术。3例患者接受了肝肾联合移植。26例患者接受了二次移植(13%),2例患者接受了三次移植(1%)。患者中男性110例,女性62例,平均年龄43.7岁(范围17个月至66岁)。移植的适应证如下:暴发性肝炎22例(12%),肝硬化104例(60.5%),其中酒精性肝硬化41例(24%),乙型肝炎后肝硬化21例(12.2%),丙型肝炎后肝硬化24例(14%),自身免疫性肝硬化6例,原发性胆汁性肝硬化7例(4%),非甲非乙型肝硬化21例(12.9%),不明原因肝硬化3例。31例患者因癌症接受肝移植。其他适应证为硬化性胆管炎5例和胆道闭锁2例。45%的患者术后恢复顺利。肝硬化患者的住院死亡率与适应证和Child-Pugh分级有关。血管外科并发症发生率为8.5%,胆道并发症发生率为6.1%,腹腔内感染发生率为9.2%,腹腔内出血发生率为5.5%。再次手术率为18.5%。23例再次移植为急诊手术,6例为择期手术(1例来自外院)。1978年至1994年患者的总体生存率,包括环孢素时代之前的患者、体外循环的使用、威斯康星溶液保存以及主要适应证为癌症的患者,1年时为69%,5年时为59%。1988年后,患者总体生存率1年时为75%,5年时为70%。移植物和患者的生存率主要与适应证有关。在暴发性和亚暴发性肝炎中,尽可能优先选择质量好的移植物。移植物1年、3年和5年的预期生存率分别为75%、70.45%和70.45%。患者预期生存率为77.3%、72.5%和72.5%。在癌症肝移植中,患者1年、3年和5年的预期生存率分别为55%、32%和23.5%。5例患者5年后存活且状况良好,其中1例因肝门部胆管癌接受了肝段切除术。在乙型肝炎后肝硬化中,患者1年、3年和5年的预期生存率分别为79%、76.5%和76.5%,酒精性肝硬化患者分别为75%、72%和72%。预期生存率与Child-Pugh分级密切相关(1年时Child A级为87%,Child B级为72.4%,Child C级为58%)。
在雷恩大学医学中心的这系列前200例肝移植中,移植物和患者的生存率取决于手术技术的发展,但也与适应证密切相关。在暴发性肝炎中,移植物的质量(尽可能避免不相容移植物)应能避免再次移植并获得接近择期移植的效果。癌症肝移植应受到限制。在肝硬化中,结果取决于Child-Pugh分级。应遵循巴黎共识会议的结论。供肝数量有限要求“优先选择”(T.E. Starzl)最能受益的患者,即病情最严重、短期生存预后最差的患者。